TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00996281
Drug: Olmesartan medoxomil and hydrochlorothiazide
Normalized name: Olmesartan Medoxomil and Hydrochlorothiazide Tablets
DrugBank: Olmesartan (DB00275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination tablet.
Study: NCT01098877
Drug: PF-04634817 Placebo
Normalized name: PF-04634817
DrugBank: PF-04634817 (DB14955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution, placebo, single dose
Study: NCT01098877
Drug: PF-04634817
Normalized name: PF-04634817
DrugBank: PF-04634817 (DB14955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution, 1mg, single dose
Study: NCT01098877
Drug: PF-04634817
Normalized name: PF-04634817
DrugBank: PF-04634817 (DB14955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution, 3mg, single dose
Study: NCT01098877
Drug: PF-04634817
Normalized name: PF-04634817
DrugBank: PF-04634817 (DB14955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution, 10mg, single dose
Study: NCT01098877
Drug: PF-04634817
Normalized name: PF-04634817
DrugBank: PF-04634817 (DB14955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution, 30mg, single dose
Study: NCT01098877
Drug: PF-04634817
Normalized name: PF-04634817
DrugBank: PF-04634817 (DB14955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution, 100mg, single dose
Study: NCT01098877
Drug: PF-04634817
Normalized name: PF-04634817
DrugBank: PF-04634817 (DB14955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution, 300mg, single dose
Study: NCT01098877
Drug: PF-04634817
Normalized name: PF-04634817
DrugBank: PF-04634817 (DB14955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution, 600mg, single dose
Study: NCT01098877
Drug: PF-04634817
Normalized name: PF-04634817
DrugBank: PF-04634817 (DB14955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution, 900mg, single dose
Study: NCT01098877
Drug: PF-04634817
Normalized name: PF-04634817
DrugBank: PF-04634817 (DB14955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution, up to 900mg, single dose after food
Study: NCT01098877
Drug: PF-04634817 Placebo
Normalized name: PF-04634817
DrugBank: PF-04634817 (DB14955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution, placebo, single dose after food
Study: NCT01794741
Drug: Fluticasone propionate nasal spray
Normalized name: fluticasone propionate Metered Dose Nasal Spray
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02699008
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Antiplatelet agent
Study: NCT02699008
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: New P2Y12 receptor inhibitor antiplatelet agent
Study: NCT04535713
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2 (Maximum Dose: 1000 mg) i.v. on Day 1 and Day 8 of Cycle 1+
Study: NCT04535713
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg/m2 (Maximum Dose: 42 mg) i.v. on Day 1 and Day 8 of Cycle 1+
Study: NCT04535713
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 240 mg i.v. on Day 1 beginnning Cycle 2+
Study: NCT01437644
Drug: botulinum toxin intramuscular injection
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: A single dose of active drug or placebo will be administered immediately prior to surgery.~The injections will be given to the anaesthetised child before the surgical procedure begins. The surgeon will perform the injections at three muscle groups around each hip: the adductors, hamstrings and iliopsoas muscles. Two units per kilogram will be given at each site. The maximum dose will be 12 units per kilogram or 500 units in total (whichever is the lesser), divided equally between six or three sites. Each active drug vial will contain 100 iu of the Botox preparation. The volume injected will be dependent on the weight of the child. Injections of normal saline will be administered in those children randomised to the placebo.
Study: NCT03054350
Drug: Vadadustat
Normalized name: vadadustat
DrugBank: Vadadustat (DB12255)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Daily oral dose
Study: NCT02351687
Drug: Sulfadoxine-pyrimethamine
Normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02351687
Drug: Albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01258153
Drug: Nepadutant oral solution
Normalized name: Nepadutant
DrugBank: Nepadutant (DB12538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration once daily for 7 days
Study: NCT01258153
Drug: Placebo matching Nepadutant oral solution
DrugBank: Nepadutant (DB12538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration once daily for 7 days
Study: NCT00881153
Drug: Cefprozil 250 mg/5 ml Oral Suspension (Sandoz GmbH)
DrugBank: Cefprozil (DB01150)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00867087
Drug: inotuzumab ozogamicin (CMC-544)
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.8 mg/m\^2 every 21 days by intravenous infusion, 3 to 6 doses
Study: NCT00867087
Drug: rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m\^2 two days before cycle 1 by intravenous infusion; 375 mg/m\^2 every 21 days by intravenous infusion, 3 to 6 doses
Study: NCT02088073
Drug: Sodium zirconium cyclosilicate
Normalized name: sodium zirconium cyclosilicate
DrugBank: Sodium zirconium cyclosilicate (DB14048)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sodium zirconium cyclosilicate
Study: NCT03871348
Drug: Cemiplimab REGN2810
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical form: solution for injection~Route of administration: intravenous
Study: NCT01023087
Drug: Polymyxin E (Colistin)
DrugBank: Colistin (DB00803)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic medication; dosage to be decided according to infectious disease consultant recommendation.
Study: NCT00975819
Drug: sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: liquid dosing based on trough levels
Study: NCT00016744
Drug: Sodium 4-Phenylbutyrate (4PBA)
Normalized name: 4-phenylbutyrate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The standard oral adult dose is 20g/day (tablets) for 4 days.
Study: NCT00016744
Drug: Unconjugated Isoflavones 100 (PTI G-4660, 87% Genistein)
Normalized name: Conjugated Estrogens
DrugBank: Flavone (DB07776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Every participant will be administered a perfusion of 50 MicroM of Genistein during the modified NPD procedure.
Study: NCT03535662
Drug: Orvepitant
Normalized name: Orvepitant
DrugBank: Orvepitant (DB12427)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose
Study: NCT03535662
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily dosing for 10 days
Study: NCT00196586
Drug: pegylated interferon alpha 2a
Normalized name: Pegylated interferon alpha-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00196586
Drug: ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01497509
Drug: Bolus 10mL 0.25% bupivacaine/ep 1:600,000; infusion 10mL/hour 0.25% bupivacaine and epi 1:800,000
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01497509
Drug: Bolus 10mL 0.25% bupivacaine, 10mcg/mL fentanyl, and epi 1:600,000; infusion 10mL/hour 0.25% bupivacaine, 2.5 mcg/mL fentanyl, and epi 1:800,000
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01497509
Drug: Bolus 10mL 0.25% bupivacaine, 5 mcg/mL fentanyl, and epi 1:600,000; infusion 10mL/hour 0.25% bupivacaine, 3.5 mcg/mL fentanyl, and epi 1:800,000
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00911092
Drug: Chemotherapy (Fluorouracil and Cisplatin)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: At weeks 1, 5, 8 and 11~* Day 1 to day 4: Fluorouracil 1 gr/m²/day~* Day 1 or 2: Cisplatin 75 mg/m²
Study: NCT02969590
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following this spontaneous cycle, participants received a single intramuscular injection of leuprolide acetate (11.25mg, LupronVR; Abbvie, Chicago, IL), a dose documented to suppress ovarian function for at least 3 months. Ovarian suppression is confirmed with serum E2 less than or equal to 35 pg/ml 21-28 day post-injection.
Study: NCT02969590
Drug: Estrogen and Progesterone Replacement
Normalized name: testosterone and estrogen
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Replace hormones exogenously to create an artificial cycle
Study: NCT02704923
Drug: Atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine eye drops (1%) administered by sublingual way (2 drops) every 6 hours
Study: NCT04384380
Drug: Hydroxychloroquine Sulfate 200 MG [Plaquenil]
Normalized name: hydroxychloroquine sulfate 200 MG [Plaquenil]
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine Sulfate is 400 mg bid on Day 1 and 200 mg bid for 6 days on Day 2-7.
Study: NCT00694096
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imaging studies with complete analyses will be provided on all patients prior to institution of sunitinib therapy as well as after therapy at various early time points (1 week in 5 patients, 2 weeks in 5 patients, 3 weeks in 5 patients or 4 weeks in 5 patients) after institution of sunitinib therapy at 37.5 mg orally/day.~Imaging studies include:~FDG-PET scans FLT-PET scans H215O-PET scans DCE-MRI scans
Study: NCT00853125
Drug: sunitinib malate
Normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib will be administered orally at a dose of 50 mg qd for 4 consecutive weeks followed by 2 weeks off for every cycle.
Study: NCT03236012
Drug: Botulinum Toxin Type A (Botox)
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Maximum dose up to 400 units given one time
Study: NCT00711490
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 20 μL (440 μg) of sirolimus were injected at baseline, Month 2, and every 2 months thereafter if re-treatment criteria were satisfied.
Study: NCT01071005
Drug: Lorelin Depot Bergamo
Normalized name: BERGAMOT
DrugBank: Bergamot oil (DB14335)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorelin Depot Bergamo, 3,75 mg, single dose.
Study: NCT01071005
Drug: Lupron Depot - Abbott
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lupron Depot 3,75 mg, single dose.
Study: NCT03023826
Drug: LY3202626 (T1-Fasting)
Normalized name: Fast Freeze
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00182767
Drug: ixabepilone
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00810485
Drug: ADX10059
Normalized name: ADX10059
DrugBank: ADX10059 (DB05070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT00810485
Drug: ADX10059 Matching Placebo
DrugBank: ADX10059 (DB05070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT01142557
Drug: Interferon beta-1a (Rebif)
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A dosage of 44 µg or 22 µg interferon beta-1a (Rebif) as subcutaneous self-injection three times a week was recommended for therapy of the included, suitable MS subjects after a creep-in phase of 4 weeks.
Study: NCT04159688
Drug: Alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol Challenge
Study: NCT01514240
Drug: D9421-C capsule 3 mg
Normalized name: 3'-C-Ethynylcytidine
DrugBank: TAS-106 (DB06656)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomised to D9421-C 9 mg will take 3 capsules of D9421-C capsule 3 mg once daily before breakfast and 4 tablets of Mesalazine tablets placebo three times a day after each meal for 8 weeks.
Study: NCT01514240
Drug: Mesalazine tablets
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients randomised to Mesalazine 3 g will take 3 capsules of D9421-C capsule placebo once daily before breakfast and 4 tablets of Mesalazine tablets 250 mg three times a day after each meal for 8 weeks.
Study: NCT00255073
Drug: baclofen
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02129478
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive olanzapine once daily starting just before the first dose of chemotherapy within the study chemotherapy block and continuing until discharge from hospital or for a maximum of 4 doses after the last dose of chemotherapy.~Olanzapine will be dosed at 0.14mg/kg/dose (maximum 10mg/dose) as a single daily oral dose rounded to the nearest increment of a half-tablet (2.5mg).
Study: NCT00004142
Drug: Floxuridine
Normalized name: Floxuridine
DrugBank: Floxuridine (DB00322)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Part of hepatic arterial chemotherapy on days 1-7. Treatment repeats every 5 weeks for 6 courses.
Study: NCT00346489
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00346489
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003136
Drug: amifostine trihydrate
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003136
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02088502
Drug: N-acetylcysteine
Normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02088502
Drug: 0.9% sodium chloride
Normalized name: LMD with 0.9% Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients are hydrated with 0.9% sodium chloride (1 mL/kg/hour) for 24 hours, 12 hours before operation. Patients with left ventricular ejection fraction less than 40% or New York Heart Association functional class III-IV, are hydrated with 0.5 mL/kg per hour.
Study: NCT03043495
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Various doses of Dexamethasone (2, 4 \& 8 mg) to be used as an Adjuvant to Local anesthetic drugs
Study: NCT01007071
Drug: Human Growth Hormone (1-134)
Normalized name: Growth hormone (human)
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to human growth hormone (1-134) for 16 weeks. In this arm, growth hormone is dosed sc on a daily basis and increased over first 6 weeks (Men: start at 0.2 mg sc/d, increase to 0.6 mg sc/d after 4 weeks. Women, postmenopausal: start at 0.3 mg sc/d, increase to 0.9 mg sc/d after 4 weeks. Women premenopausal or on estrogen: start at 0.6 mg sc/d, increase to 1.3 mg sc/d after 4 weeks.) Dose adjustments based on serum IGF-1 levels at 6 and 12 weeks, with final IGF-1 measurement for efficacy performed at 16 weeks, with goal in range of -0.5 SD to +2SD. An elevated serum IGF-1 value will result in a 20% dose reduction in GH in an active and random placebo patient. Similarly, a low serum IGF-1 will result in a 20% dose increase in an active and random placebo subject.
Study: NCT01341301
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV or PO
Study: NCT01341301
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or PO
Study: NCT02273635
Drug: Andrographolides
Normalized name: Andrographis paniculata top extract
DrugBank: Andrographolide (DB05767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 140 mg andrographolides coated tablets twice a day orally administered for 24 months.
Study: NCT02594098
Drug: Secukinumab
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: At Weeks 0, 1, 2, 3, 4 and every 2 weeks thereafter through and including Week 12 in phase 1 of the study.
Study: NCT01897753
Drug: growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 36 months
Study: NCT00402714
Drug: Pentostatin
Normalized name: Pentostatin
DrugBank: Pentostatin (DB00552)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pentostatin 8mg/m2 over 48 hours by continuous infusion
Study: NCT00316095
Drug: telmisartan
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01591421
Drug: Panitumumab
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV; Every two weeks starting day 1 cycle 1 (i.e. day 1 and 15 each 28 day cycle)
Study: NCT00145444
Drug: olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00145444
Drug: ziprasidone
Normalized name: Ziprasidone
DrugBank: Ziprasidone (DB00246)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01709942
Drug: degarelix (long acting GnRH antagonist)
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg of degarelix the first day of menstrual cycle before starting with gonadotrophins administration
Study: NCT01709942
Drug: cetrorelix 0.25mg
DrugBank: Cetrorelix (DB00050)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25mg of cetrorelix during treatment with gonadotrophins when estradiol levels were \>300pg/ml
Study: NCT03351686
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (Kepron, Amoun, Egypt) was given slowly intravenously over 10 minutes just before the skin incision of elective cesarean section to group A. Tranexamic acid injection was prepared by diluting 1g (10 mL) tranexamic acid into 20 ml of 5% glucose.
Study: NCT04171180
Drug: budesonide/formoterol
Normalized name: BUDESONIDE/FORMOTEROL
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: apply different dosage of budesonide/formoterol in two groups and evaluate the treatment effects.
Study: NCT00257595
Drug: Cetirizine Dry Syrup
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04231214
Drug: Olodaterol-Tiotropium
Normalized name: olodaterol-tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5µg Olodaterol and 5 µg Tiotropium via the soft mist inhaler Respimat®, administered once on Day 1 or Day 9 and daily from Day 10 to Day 24
Study: NCT00330044
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01316952
Drug: Carvedilol immediate release only
Normalized name: carvedilol Extended Release Oral Capsule
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All dosages of carvedilol immediate release
Study: NCT01316952
Drug: Carvedilol extended release only
Normalized name: carvedilol Extended Release Oral Capsule
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All dosages of carvedilol extended release
Study: NCT00199004
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00199004
Drug: Daunorubicin
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01093781
Drug: Aliskiren
Normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aliskiren dose will begin with 150mg per day and later up-titrated to the maximum available dose of 300mg per day.
Study: NCT00199004
Drug: Asparaginase
Normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00199004
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00199004
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00199004
Drug: Vindesine
Normalized name: vindesine
DrugBank: Vindesine (DB00309)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00199004
Drug: VP16
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00199004
Drug: Adriamycin
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00199004
Drug: Thioguanine
Normalized name: Thioguanine
DrugBank: Tioguanine (DB00352)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00199004
Drug: VM26
Normalized name: Teniposide
DrugBank: Teniposide (DB00444)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00199004
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00871546
Drug: SCH 727965
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 727965 50 mg/m2 IV on Day 1 of each 21-day cycle until disease progression.
Study: NCT00871546
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib 1.3 mg/m2 IV on Days 1, 4, 8, and 11 of each 21-day cycle until disease progression.
Study: NCT00002427
Drug: Hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002427
Drug: Stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002427
Drug: Didanosine
Normalized name: Didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00048815
Drug: Citalopram
Normalized name: Citalopram
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Established Selective Serotonin Reuptake Inhibitor antidepressant
Study: NCT00048815
Drug: St. John's Wort
Normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural extract from the St. John's Wort plant.